Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults

Results of the "cOPA" pilot randomized trial

A. Gori, G. Rizzardini, B. Van'T Land, K. B. Amor, J. Van Schaik, C. Torti, T. Quirino, C. Tincati, A. Bandera, J. Knol, K. Benlhassan-Chahour, D. Trabattoni, D. Bray, A. Vriesema, G. Welling, J. Garssen, M. Clerici

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Intestinal mucosal immune system is an early target for human immunodeficiency virus type 1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal microbiota composition. We evaluated the effects of a prebiotic oligosaccharide mixture in highly active antiretroviral therapy (HAART)-naive HIV-1-infected adults. In a pilot double-blind, randomized, placebo-controlled study, 57 HAART-naive HIV-1-infected patients received a unique oligosaccharide mixture (15 or 30 g short chain galactooligosaccharides/long chain fructooligosaccharides/pectin hydrolysate-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) daily) or a placebo for 12 weeks. Microbiota composition improved significantly with increased bifidobacteria, decreased Clostridium coccoides/Eubacterium rectale cluster, and decreased pathogenic Clostridium lituseburense/Clostridium histolyticum group levels upon prebiotic supplementation. In addition, a reduction of soluble CD14 (sCD14), activated CD4 +/CD25 + T cells, and significantly increased natural killer (NK) cell activity when compared with control group were seen in the treatment group. The results of this pilot trial highly significantly show that dietary supplementation with a prebiotic oligosaccharide mixture results in improvement of the gut microbiota composition, reduction of sCD14, CD4 + T-cell activation (CD25), and improved NK cell activity in HAART-naive HIV-infected individuals.

Original languageEnglish
Pages (from-to)554-563
Number of pages10
JournalMucosal Immunology
Volume4
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Prebiotics
Highly Active Antiretroviral Therapy
Oligosaccharides
HIV
HIV-1
Clostridium
Microbiota
T-Lymphocytes
Natural Killer Cells
Clostridium histolyticum
Placebos
Eubacterium
Bifidobacterium
Virus Diseases
Dietary Supplements
Immune System
Control Groups
Gastrointestinal Microbiome
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults : Results of the "cOPA" pilot randomized trial. / Gori, A.; Rizzardini, G.; Van'T Land, B.; Amor, K. B.; Van Schaik, J.; Torti, C.; Quirino, T.; Tincati, C.; Bandera, A.; Knol, J.; Benlhassan-Chahour, K.; Trabattoni, D.; Bray, D.; Vriesema, A.; Welling, G.; Garssen, J.; Clerici, M.

In: Mucosal Immunology, Vol. 4, No. 5, 09.2011, p. 554-563.

Research output: Contribution to journalArticle

Gori, A, Rizzardini, G, Van'T Land, B, Amor, KB, Van Schaik, J, Torti, C, Quirino, T, Tincati, C, Bandera, A, Knol, J, Benlhassan-Chahour, K, Trabattoni, D, Bray, D, Vriesema, A, Welling, G, Garssen, J & Clerici, M 2011, 'Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial', Mucosal Immunology, vol. 4, no. 5, pp. 554-563. https://doi.org/10.1038/mi.2011.15
Gori, A. ; Rizzardini, G. ; Van'T Land, B. ; Amor, K. B. ; Van Schaik, J. ; Torti, C. ; Quirino, T. ; Tincati, C. ; Bandera, A. ; Knol, J. ; Benlhassan-Chahour, K. ; Trabattoni, D. ; Bray, D. ; Vriesema, A. ; Welling, G. ; Garssen, J. ; Clerici, M. / Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults : Results of the "cOPA" pilot randomized trial. In: Mucosal Immunology. 2011 ; Vol. 4, No. 5. pp. 554-563.
@article{c79c83bd1f81417988d60833b3ad79b8,
title = "Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the {"}cOPA{"} pilot randomized trial",
abstract = "Intestinal mucosal immune system is an early target for human immunodeficiency virus type 1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal microbiota composition. We evaluated the effects of a prebiotic oligosaccharide mixture in highly active antiretroviral therapy (HAART)-naive HIV-1-infected adults. In a pilot double-blind, randomized, placebo-controlled study, 57 HAART-naive HIV-1-infected patients received a unique oligosaccharide mixture (15 or 30 g short chain galactooligosaccharides/long chain fructooligosaccharides/pectin hydrolysate-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) daily) or a placebo for 12 weeks. Microbiota composition improved significantly with increased bifidobacteria, decreased Clostridium coccoides/Eubacterium rectale cluster, and decreased pathogenic Clostridium lituseburense/Clostridium histolyticum group levels upon prebiotic supplementation. In addition, a reduction of soluble CD14 (sCD14), activated CD4 +/CD25 + T cells, and significantly increased natural killer (NK) cell activity when compared with control group were seen in the treatment group. The results of this pilot trial highly significantly show that dietary supplementation with a prebiotic oligosaccharide mixture results in improvement of the gut microbiota composition, reduction of sCD14, CD4 + T-cell activation (CD25), and improved NK cell activity in HAART-naive HIV-infected individuals.",
author = "A. Gori and G. Rizzardini and {Van'T Land}, B. and Amor, {K. B.} and {Van Schaik}, J. and C. Torti and T. Quirino and C. Tincati and A. Bandera and J. Knol and K. Benlhassan-Chahour and D. Trabattoni and D. Bray and A. Vriesema and G. Welling and J. Garssen and M. Clerici",
year = "2011",
month = "9",
doi = "10.1038/mi.2011.15",
language = "English",
volume = "4",
pages = "554--563",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults

T2 - Results of the "cOPA" pilot randomized trial

AU - Gori, A.

AU - Rizzardini, G.

AU - Van'T Land, B.

AU - Amor, K. B.

AU - Van Schaik, J.

AU - Torti, C.

AU - Quirino, T.

AU - Tincati, C.

AU - Bandera, A.

AU - Knol, J.

AU - Benlhassan-Chahour, K.

AU - Trabattoni, D.

AU - Bray, D.

AU - Vriesema, A.

AU - Welling, G.

AU - Garssen, J.

AU - Clerici, M.

PY - 2011/9

Y1 - 2011/9

N2 - Intestinal mucosal immune system is an early target for human immunodeficiency virus type 1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal microbiota composition. We evaluated the effects of a prebiotic oligosaccharide mixture in highly active antiretroviral therapy (HAART)-naive HIV-1-infected adults. In a pilot double-blind, randomized, placebo-controlled study, 57 HAART-naive HIV-1-infected patients received a unique oligosaccharide mixture (15 or 30 g short chain galactooligosaccharides/long chain fructooligosaccharides/pectin hydrolysate-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) daily) or a placebo for 12 weeks. Microbiota composition improved significantly with increased bifidobacteria, decreased Clostridium coccoides/Eubacterium rectale cluster, and decreased pathogenic Clostridium lituseburense/Clostridium histolyticum group levels upon prebiotic supplementation. In addition, a reduction of soluble CD14 (sCD14), activated CD4 +/CD25 + T cells, and significantly increased natural killer (NK) cell activity when compared with control group were seen in the treatment group. The results of this pilot trial highly significantly show that dietary supplementation with a prebiotic oligosaccharide mixture results in improvement of the gut microbiota composition, reduction of sCD14, CD4 + T-cell activation (CD25), and improved NK cell activity in HAART-naive HIV-infected individuals.

AB - Intestinal mucosal immune system is an early target for human immunodeficiency virus type 1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal microbiota composition. We evaluated the effects of a prebiotic oligosaccharide mixture in highly active antiretroviral therapy (HAART)-naive HIV-1-infected adults. In a pilot double-blind, randomized, placebo-controlled study, 57 HAART-naive HIV-1-infected patients received a unique oligosaccharide mixture (15 or 30 g short chain galactooligosaccharides/long chain fructooligosaccharides/pectin hydrolysate-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) daily) or a placebo for 12 weeks. Microbiota composition improved significantly with increased bifidobacteria, decreased Clostridium coccoides/Eubacterium rectale cluster, and decreased pathogenic Clostridium lituseburense/Clostridium histolyticum group levels upon prebiotic supplementation. In addition, a reduction of soluble CD14 (sCD14), activated CD4 +/CD25 + T cells, and significantly increased natural killer (NK) cell activity when compared with control group were seen in the treatment group. The results of this pilot trial highly significantly show that dietary supplementation with a prebiotic oligosaccharide mixture results in improvement of the gut microbiota composition, reduction of sCD14, CD4 + T-cell activation (CD25), and improved NK cell activity in HAART-naive HIV-infected individuals.

UR - http://www.scopus.com/inward/record.url?scp=84860390171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860390171&partnerID=8YFLogxK

U2 - 10.1038/mi.2011.15

DO - 10.1038/mi.2011.15

M3 - Article

VL - 4

SP - 554

EP - 563

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 5

ER -